Published in AIDS Weekly, May 8th, 2006
Study 1: An HIV-1 recombinant canarypox vaccine is safe and immunogenic in infants of HIV-1-infected mothers.
"Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1).
"HIV-1-exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks," scientists in the United States report.
According to D.C. Johnson and colleagues at Sinai Children's Hospital and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-05-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.